

PATRICK J. LEAHY, VERMONT, CHAIRMAN

HERB KOHL, WISCONSIN
DIANNE FEINSTEIN, CALIFORNIA
CHARLES E. SCHUMER, NEW YORK
RICHARD J. DURBIN, ILLINOIS
SHELDON WHITEHOUSE, RHODE ISLAND
AMY KLOBUCHAR, MINNESOTA
AL FRANKEN, MINNESOTA
CHRISTOPHER A. COONS, DELAWARE
RICHARD BLUMENTHAL, CONNECTICUT

CHARLES E. GRASSLEY, IOWA
ORRIN G. HATCH, UTAH
JON KYL, ARIZONA
JEFF SESSIONS, ALABAMA
LINDSEY O. GRAHAM, SOUTH CAROLINA
JOHN CORNYN, TEXAS
MICHAEL S. LEE, UTAH
TOM COBURN, OKLAHOMA

United States Senate

COMMITTEE ON THE JUDICIARY
WASHINGTON, DC 20510-6275

BRUCE A. COHEN, *Chief Counsel and Staff Director*
KOLAN L. DAVIS, *Republican Chief Counsel and Staff Director*

May 4, 2011

Via Electronic Transmission

Laurence Hausner
Chief Executive Officer
American Diabetes Association
1701 N. Beauregard Street
Alexandria, VA 22311

Dear Mr. Hausner:

In December 2009, I asked for an accounting of industry funding that American Diabetes Association (ADA) receives from pharmaceutical and medical device companies as well as foundations established by these companies or the insurance industry. I appreciate your response, which I have attached to this letter. I write today to follow up on any efforts by your organization to improve transparency and accountability in its relationships with the pharmaceutical and device industries.

As I stated in my previous letter, I started my inquiry, in part, as a result of accounts documenting the lack of transparency in financial relationships between the pharmaceutical industry and nonprofit health and medical organizations. Specifically, I cited the April 2008 article in *The Wall Street Journal*, which reported that industry representatives, including ten major drug companies, had formed a coalition to promote looser restrictions on off-label marketing.¹ The coalition had asked the National Alliance on Mental Illness (NAMI) to speak in favor of this issue.

In response to my concerns in my April 2009 letter to NAMI, NAMI began to voluntarily disclose to the public any amount of funding exceeding \$5,000 that it received from pharmaceutical companies and foundations on its website. Further, NAMI began to provide a brief description of the purpose of the funding on its website. I commend NAMI for its leadership and had hoped that when I reached out to your organization and 32 others, your organization would follow NAMI's example and begin posting similar funding information on ADA's website.

As of the date of this letter, it appears that your organization has taken steps to identify on its website the corporate or industry sponsors and their range of funding support. However, the

¹ Alicia Mundy, "Off-Label Use of Drugs Gets a Push --- Big Pharma Lobbies Washington to Relax Rules on Marketing," *The Wall Street Journal*, April 18, 2008.

website does not specify the purposes of that funding. If ADA is currently taking steps to further enhance the transparency of its financial relationships with the pharmaceutical and device industries, I would appreciate information regarding those steps. In particular, please state whether or not ADA will be adding information in the future about the purpose of the funding it receives. If not, please explain why not.

The Medicare Payment Advisory Commission (MedPAC) recommended in a report to Congress in March 2009 that Congress require that pharmaceutical and device companies report their financial relationships with physician groups, patient organizations, and others. More specifically MedPAC said the following:

Given the potential benefits of public reporting, we recommend that the Congress mandate the reporting of comprehensive information on industry relationships with physicians and other health care entities and that the Secretary post this information on a public searchable website.²

MedPAC then went on to say in Recommendation 5-1 that:

The Congress should require all manufacturers and distributors of drugs, biologicals, medical devices, and medical supplies (and their subsidiaries) to report to the Secretary their financial relationship with: . . . physician groups and other prescribers . . . patient organizations; and professional organizations.³

I look forward to working with you and other health and medical organizations to further increase sunshine on financial relationships.

Thank you for your cooperation and attention in this matter. I would appreciate a response by May 25, 2011. If you have any questions, please do not hesitate to contact Brian Downey for the Committee on the Judiciary at (202) 224-5225.

Sincerely,



Charles E. Grassley
Ranking Member

Attachments

² Medicare Payment Advisory Commission, "Public reporting of physicians' financial relationships," Report to Congress: Medicare Payment Policy, March 2009.

³ *Id.*

January 28, 2010

Honorable Charles E. Grassley
Ranking Member
Committee on Finance
United States Senate
Washington, D.C. 20510-6200

Dear Senator Grassley:

The American Diabetes Association (the Association) is pleased to provide this letter and supporting documentation in response to your request of December 7, 2009.

Overview and Mission

The Association is the nation's leading 501(c)(3) voluntary health organization providing diabetes research, information, advocacy, and public awareness. Founded in 1940, the Association conducts programs in all 50 states and the District of Columbia, reaching hundreds of communities. Diabetes has reached epidemic proportions: almost 24,000,000 men, women and children in America have diabetes, and another 57,000,000 have pre-diabetes.

The mission of the Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. To fulfill this mission, the Association funds scientific research, publishes scientific findings, provides information and other services to people with diabetes, their families, health professionals and the public. The Association is also actively involved in advocating for more scientific research and for the rights of people with diabetes.

To help us fulfill our mission, the Association has an ongoing process of identifying, developing and maintaining positive relationships with corporations, in order to reach people, raise dollars and recruit volunteers.

Financial Support

The Association's total financial support in 2009 is projected to be \$205 million. Most of the support comes from individual donations, including participation in the Association's special events. The Association generated \$15.4 million from pharmaceutical, medical device and insurance companies, and foundations established by these companies representing 7.5% of total support.

Revenues from these companies are primarily in two categories:

1) Grants, contributions and sponsorships which include:

- Unrestricted support for continuing medical education programs. These programs help to keep health professionals up to date with the latest information about the disease and its related comorbidities and complications.
- Sponsorships of Association events, programs and initiatives--at both the national and local level. These programs include the Association's educational and fundraising *Step Out For Diabetes®* Walks, the Association educational and fundraising *Tour de Cure®* bicycling events, and the Association's consumer educational exhibition, *Diabetes EXPO®*.

- Support for educational initiatives reaching healthcare professionals and consumers such as the *Cardiometabolic Risk Initiative*, designed to increase awareness about the prevention of diabetes and heart disease.

2) "Fee for Exchange" transactions which include:

- Advertising in the Association's journals and publications such as *Diabetes*®, *Diabetes Care*®, *Clinical Diabetes*®, and *Diabetes Forecast*®.
- Exhibiting at the Association's meetings such as the annual Scientific Sessions, the world's largest diabetes scientific conference.

Specific Information Requested

Question 1: Please explain what policies, if any that the American Diabetes Association plans to adopt to ensure transparency of funding in order to provide a greater public trust in the independence of your organization.

The Association has been and will be transparent in disclosing and publicizing our support from corporate sources, and will continue to follow established best practices for voluntary health organizations.

A few examples:

- We have clear guidelines on the acceptance/rejection of revenue found in "Guidelines For Implementing The Uniform Policy for the Acceptance/Rejection of Revenue." (See Attachment A.)
- The Association discloses the financial support of companies at various financial levels, including the Banting Circle (\$500,000 and above) and Banting Circle Elite (\$1 million +). We publish on our website the total annual revenues each pharmaceutical and device company provides. In addition, advertisements acknowledging the Banting Circle Elite and Banting Circle companies appear in our consumer and professional journals.
- As a member of the National Health Council, we comply with their policies on disclosing corporate revenue.
- As a provider of continuing medical education, it is the Association's policy to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. All participating faculty and planning committee members are required to disclose to the program audience any financial relationships related to the subject matter of the program prior to participation. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of the disclosure is not to prevent a planner or presenter from being involved in the activity, but rather to provide participants with information on which they can make their own judgments. All disclosures are printed in the final program and presenters are required to have a slide at the beginning of the presentation. Employees of pharmaceutical companies are not permitted to serve on a planning committee nor serve as faculty, if the program is accredited.

Question 2: Please explain your policies on disclosure of outside income by your top executives and board members.

The Association requires all members of the Board of Directors, members of Board appointed committees and staff to act solely in the best interest of the Association without regard to their personal or business interests.

The Association recognizes that there may be instances where a person in a position listed above may appear to have a conflict of interest, if that person has a business or personal interest that is related to an interest of the Association.

To identify and manage potential conflicts of interest, Officers, Directors, members of select Board appointed committees and their related subcommittees, journal/periodical editors, and senior staff of the Association must annually disclose any potential conflicts of interest. Our legal staff provides in-person training on Fiduciary Duties to new Board members.

These requirements were originally established as the *Duality of Interest Policy* in June 1979. The policy has been updated over the years and is now known as the Association's *Conflict of Interest Policy*. The *Conflict of Interest Policy* is reviewed by the Board of Directors at least once every three years for confirmation or adjustment.

A copy of the policy and a *Conflict of Interest Disclosure Policy* (Attachment C) is attached.

Question 3: Please provide the disclosures of outside income filed with your organizations by your top executives and board members.

(See Attachment D)

Please let Tekisha Dawn Everette, our Director of Federal Government Affairs, know if you have any additional questions. She can be reached at (703) 253-4375 or teverette@diabetes.org.

Sincerely,



M. Vaheeda Bennett
Executive Vice-President, Development

Attachments

- A_ Guidelines For Implementing The Uniform Policy For Acceptance/Rejection of Revenue
- B_ Summary of Pharmaceutical Contributions 2006-2009
- C_ Conflict of Interest Policy
- D_ Association Conflict of Interest Disclosures

American Diabetes Association
Summary of Pharmaceutical Revenues
2006-2009
Attachment B

	2006	2007	2008	2009
Abbott Laboratories	\$ 453,647	\$ -	\$ -	\$ -
Abbott Laboratories/Abbott Diabetes Care	\$ 862,251	\$ 636,675	\$ 1,113,040	\$ 722,298
Aetna	\$ 99,241	\$ 243,474	\$ 225,616	\$ 277,096
Amylin Pharmaceuticals	\$ 318,174	\$ 1,145,860	\$ 845,410	\$ 907,600
Anthem Blue Cross Blue Shield	\$ 32,252	\$ 29,211	\$ 38,900	\$ -
AstraZeneca LP	\$ 429,557	\$ 246,550	\$ 73,437	\$ 184,412
AstraZeneca/ Bristol- Myers Squibb	\$ -	\$ -	\$ 318,085	\$ 684,000
Baxter Healthcare	\$ 500,000	\$ 500,000	\$ -	\$ -
Bayer Healthcare, Diagnostics Corp.	\$ 1,154,043	\$ 775,029	\$ 308,613	\$ 292,677
BD Consumer Healthcare	\$ 1,285,050	\$ 423,795	\$ 714,286	\$ 552,617
Blue Cross Blue Shield	\$ 241,720	\$ 275,130	\$ 294,774	\$ 119,147
Boehringer-Ingelheim	\$ -	\$ 152,600	\$ 266,000	\$ 413,600
Bristol-Myers Squibb	\$ 392,644	\$ 190,284	\$ 254,648	\$ 232,551
Eli Lilly and Company	\$ 1,460,942	\$ 1,987,109	\$ 1,443,588	\$ 1,107,399
Daichi-Sankyo Pharmaceuticals	\$ -	\$ -	\$ -	\$ 155,401
GlaxoSmithKline	\$ 1,532,916	\$ 296,698	\$ 524,520	\$ 50,473
Humana	\$ 56,288	\$ 58,800	\$ 64,025	\$ 92,375
Johnson & Johnson	\$ 16,268	\$ 17,287	\$ 22,919	\$ 146,901
King Pharmaceuticals	\$ -	\$ 100,000	\$ -	\$ -
LifeScan, Inc.	\$ 1,211,769	\$ 1,105,866	\$ 319,752	\$ 170,450
Medtronic MiniMed	\$ 195,579	\$ 335,565	\$ 387,068	\$ 286,056
Merck & Co., Inc.	\$ 860,500	\$ 3,100,195	\$ 1,436,690	\$ 1,166,018
Merck/ Schering- Plough	\$ 158,194	\$ 206,000	\$ 108,600	\$ 122,900
Novartis Pharmaceuticals Corp.	\$ 2,493,450	\$ 1,491,280	\$ 287,980	\$ 23,495
Novo Nordisk Pharmaceuticals	\$ 1,878,611	\$ 2,122,385	\$ 2,028,210	\$ 2,209,292
Pfizer Inc	\$ 1,424,025	\$ 2,245,882	\$ 704,491	\$ 578,021
Roche Pharmaceuticals	\$ -	\$ -	\$ -	\$ 500,000
Roche Diagnostics Corporation	\$ 520,170	\$ 555,360	\$ 581,636	\$ 371,541
sanofi-aventis	\$ 2,224,366	\$ 2,114,731	\$ 2,260,448	\$ 1,075,903

American Diabetes Association
Summary of Pharmaceutical Revenues
2006-2009
Attachment B

	2006	2007	2008	2009
SOILL	\$ 100,000	\$ -	\$ -	\$ -
Solvay Pharmaceuticals	\$ -	\$ -	\$ 2,400,000	\$ 690,000
Takeda Pharmaceuticals North America, Inc.	\$ 1,489,153	\$ 1,993,593	\$ 2,833,900	\$ 1,448,457
United Healthcare	\$ 123,860	\$ 68,170	\$ 86,666	\$ 381,783
WellPoint Foundation	\$ 33,507	\$ 36,957	\$ 1,049	\$ 669,526

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
<u>Abbott Laboratories, Abbott Diabetes Care</u>	2006	
A1C Project		\$150,000
Support of Local Events and Programs		\$30,975
Advertising in ADA Publications		\$381,676
Corporate Sponsored Symposia		\$25,000
Diabetes Care Coalition		\$275,000
<i>Sub-Total</i>		\$862,651
<u>Abbott Laboratories/Abbott Diabetes Care</u>	2007	
Latino Initiative (Year 1 of 2)		\$100,000
Support of Local Events and Programs		\$241,410
ADA Latino Initiative- Chicago (Year 1)		\$75,000
EXPO		\$38,665
Corporate Sponsored Symposia		\$25,000
Exhibiting		\$156,600
<i>Sub-Total</i>		\$636,675
<u>Abbott Laboratories, Abbott Diabetes Care</u>	2008	
Latino Initiative (Year 2 of 2)		\$150,000
Support of Local Events and Programs		\$386,064
EXPO		\$56,900
Product Education Showcase at Postgraduate Course		\$5,000
Advertising in ADA Publications		\$329,476
Exhibiting at Scientific Sessions		\$185,600
<i>Sub-Total</i>		\$1,113,040
<u>Abbott Laboratories, Abbott Diabetes Care</u>	2009	
Support of Local Events and Programs		\$274,389
EXPO		\$43,000
Safe at School Program		\$35,000
Advertising in ADA Publications		\$216,109
Exhibiting at Scientific Sessions		\$148,800
Product Education Showcase at Postgraduate Course		\$5,000
<i>Sub-Total</i>		\$722,298
<u>Abbott Laboratories</u>	2006	
African-American Program		\$100,000
Support of Local Events and Programs		\$82,526
Advertising in ADA Publications		\$41,097
EXPO		\$53,824
Exhibiting at Scientific Sessions		\$151,200
Corporate Supported Symposia		\$25,000
<i>Sub-Total</i>		\$453,647

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
Aetna	2006	
Support of Local Events, Expo and Programs		\$99,241
	<i>Sub-Total</i>	\$99,241
Aetna	2007	
Support of Local Events, Expo and Programs		\$243,474
	<i>Sub-Total</i>	\$243,474
Aetna	2008	
Support of Local Events, Expo and Programs		\$225,616
	<i>Sub-Total</i>	\$225,616
Aetna	2009	
Support of Local Events, Expo and Programs		\$277,096
	<i>Sub-Total</i>	\$277,096
Amylin Pharmaceuticals	2006	
Beta Cell Research Conference		\$93,187
Support of Local Events and Programs		\$36,775
Advertising in ADA Publications		\$9,012
EXPO		\$7,400
Scientific Sessions--Exhibiting		\$44,800
Corporate Sponsored Symposia		\$25,000
Scientific Sessions Sponsorship of Bus Routes		\$100,000
PostGraduate Course--Product Showcase		\$2,000
	<i>Sub-Total</i>	\$318,174
Amylin Pharmaceuticals	2007	
ADA Research (Year 1 of 3)		\$500,000
Support of Local Events and Programs		\$71,350
Advertising in ADA Publications		\$29,680
Expo		\$4,200
Scientific Sessions Webcast		\$150,000
Scientific Sessions Final Program		\$100,000
Scientific Sessions Corporate Sponsored Symposia		\$50,000
Scientific Sessions Bus Route Sponsorship		\$50,000
Exhibiting at Scientific Sessions		\$70,000
2008 Scientific Sessions		\$115,000
PostGraduate Course Product Showcase		\$5,000
	<i>Sub-Total</i>	\$1,145,230

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
Amylin Pharmaceuticals	2008	
Support of Local Events and Programs		\$6,000
Advertising in ADA Publications		\$68,410
Expo		\$3,500
ADA Research Foundation		\$500,000
Scientific Sessions Bus Route & Final Program		\$190,000
Product Education Showcase at Postgraduate Course		\$5,000
Exhibiting at Scientific Sessions		\$72,500
	<i>Sub-Total</i>	\$845,410
Amylin Pharmaceuticals	2009	
Support of Local Events and Programs		\$172,900
Expo		\$900
ADA Research Grant		\$500,000
Scientific Sessions Day-At-A-Glance & Corporate Symposia		\$85,000
Exhibiting at Scientific Sessions		\$148,800
	<i>Sub-Total</i>	\$907,600
Anthem Blue Cross Blue Shield	2006	
Support of Local Events, Expo and Programs		\$32,252
	<i>Sub-Total</i>	\$32,252
Anthem Blue Cross Blue Shield	2007	
Support of Local Events, Expo and Programs		\$29,211
	<i>Sub-Total</i>	\$29,211
Anthem Blue Cross Blue Shield	2008	
Support of Local Events, Expo and Programs		\$38,900
	<i>Sub-Total</i>	\$38,900
AstraZeneca	2006	
Research Conference (Advanced Glycation End Products)		\$15,000
Support of Local Events and Programs (AstraZeneca Charity Challenge)		\$100,000
Advertising in ADA Publications		\$71,257
EXPO		\$2,750
Scientific Sessions Exhibiting		\$80,800
Scientific Sessions Corporate Sponsored Symposia		\$25,000
Scientific Sessions Sponsorship--Posters 2 View		\$85,000

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
PostGraduate Course (General Session Sponsorship)		<u>\$10,000</u>
	<i>Sub-Total</i>	\$429,557
AstraZeneca	2007	
Support of Local Events and Programs		\$129,550
EXPO		<u>\$50,000</u>
Scientific Sessions Corporate Symposia		<u>\$25,000</u>
Scientific Sessions Exhibiting		<u>\$42,000</u>
	<i>Sub-Total</i>	\$246,550
AstraZeneca	2008	
Support of Local Events and Programs		\$63,437
EXPO		<u>\$10,000</u>
	<i>Sub-Total</i>	\$73,437
AstraZeneca	2009	
Support of Local Events and Programs		\$48,900
Advertising in ADA Publications		<u>\$135,512</u>
	<i>Sub-Total</i>	\$184,412
AstraZeneca/Bristol-Myers Squibb	2008	
Support of Local Events and Programs		\$108,635
Scientific Sessions Corporate Symposia & Final Program		<u>\$95,000</u>
Advertising in ADA Publications		<u>\$114,450</u>
	<i>Sub-Total</i>	\$318,085
AstraZeneca/Bristol-Myers Squibb	2009	
EAG Toolkit		\$400,000
Scientific Sessions (2) Corporate Symposia & Advance Program		<u>\$160,000</u>
Scientific Sessions Exhibiting		<u>\$124,000</u>
	<i>Sub-Total</i>	\$684,000
Baxter Healthcare		
Study on Developing a Healthcare Efficiency Measure (Year 1); Sponsorship of Kidney Disease module for African-American program	2006	<u>\$500,000</u>
	<i>Sub-Total</i>	\$500,000
Study on Developing a Healthcare Efficiency Measure (Year 2); Sponsorship of Kidney Disease module for African-American program	2007	<u>\$500,000</u>

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
	Sub-Total	\$500,000
<u>Bayer HealthCare</u>	2006	
A1c Project		\$300,000
Support of Local Events and Programs		\$63,425
Advertising in ADA Publications		\$368,266
EXPO		\$35,352
Exhibiting (Scientific Sessions)		\$112,000
Diabetes Care Coalition		<u>\$275,000</u>
	<i>Sub-Total</i>	\$1,154,043
<u>Bayer HealthCare</u>	2007	
Diabetes Screening Project		\$175,000
Support of Local Events and Programs		\$38,200
Advertising in ADA Publications		\$104,604
EXPO		\$31,025
Exhibiting (Scientific Sessions)		\$121,800
Corporate Donation		\$30,000
Diabetes Care Coalition		<u>\$275,000</u>
	<i>Sub-Total</i>	\$775,029
<u>Bayer HealthCare</u>	2008	
Support of Local Events and Programs		\$61,949
Advertising in ADA Publications		\$191,814
EXPO		\$34,000
Exhibiting (Scientific Sessions)		<u>\$116,800</u>
	<i>Sub-Total</i>	\$404,563
<u>Bayer HealthCare</u>	2009	
Support of Local Events and Programs		\$41,757
Advertising in ADA Publications		\$21,520
EXPO		\$30,600
Exhibiting (Scientific Sessions)		\$148,800
Scientific Sessions-Corporate Symposia		\$50,000
	<i>Sub-Total</i>	\$292,677
<u>BD Diabetes</u>	2006	
ADA Research Grant		\$100,000
Support of Local Events and Programs		\$95,900
Advertising in ADA Publications		\$612,986
EXPO		\$58,400
Exhibiting (Scientific Sessions)		\$70,000
PG Product Showcase		\$2,000
In-Kind Contributions For Diabetes Camps		\$183,750

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
BD Diabetes Care		<u>\$275,000</u>
	<i>Sub-Total</i>	\$1,285,050
BD Diabetes	2007	
Support of Local Events and Programs		\$37,500
Advertising in ADA Publications		\$261,295
EXPO		\$52,500
Exhibiting		<u>\$72,500</u>
	<i>Sub-Total</i>	\$423,795
BD Diabetes	2008	
Support of Local Events and Programs		\$296,256
Advertising in ADA Publications		\$375,695
EXPO		\$14,135
Exhibiting		\$23,200
Product Education Showcase at Postgraduate Course		\$5,000
	<i>Sub-Total</i>	\$714,286
BD Diabetes	2009	
Support of Local Events and Programs		\$89,327
Advertising in ADA Publications		\$421,190
EXPO		\$17,300
Exhibiting		<u>\$24,800</u>
	<i>Sub-Total</i>	\$552,617
Blue Cross Blue Shield	2006	
Support of Local Events, Expo and Programs		<u>\$241,720</u>
	<i>Sub-Total</i>	\$241,720
Blue Cross Blue Shield	2007	
Support of Local Events, Expo and Programs		<u>\$275,130</u>
	<i>Sub-Total</i>	\$275,130
Blue Cross Blue Shield	2008	
Support of Local Events, Expo and Programs		<u>\$294,774</u>
	<i>Sub-Total</i>	\$294,774
Blue Cross Blue Shield	2009	
Support of Local Events, Expo and Programs		<u>\$119,147</u>
	<i>Sub-Total</i>	\$119,147

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
<u>Boehringer-Ingelheim</u>	2007	
Exhibiting (Scientific Sessions)		\$127,600
Scientific Sessions Corporate Sponsored Symposia		\$25,000
	<i>Sub-Total</i>	\$152,600
<u>Boehringer-Ingelheim</u>	2008	
Exhibiting (Scientific Sessions)		\$116,000
Scientific Sessions 2 Bus Routes		\$150,000
	<i>Sub-Total</i>	\$266,000
<u>Boehringer-Ingelheim</u>	2009	
Support of Local Events and Programs		\$10,000
Diabetes Case Simulations		\$200,000
Exhibiting (Scientific Sessions)		\$18,600
Scientific Sessions Bus Routes, Corporate Symposia & Patron		\$185,000
	<i>Sub-Total</i>	\$413,600
<u>Bristol Myers-Squibb</u>	2006	
Tour de Cure Sponsorship		\$250,000
Support of Local Events and Programs		\$230,000
Advertising in ADA Publications		\$76,944
EXPO		\$900
Exhibiting (Scientific Sessions)		\$16,800
Scientific Sessions (Corporate Sponsored Symposia)		\$25,000
	<i>Sub-Total</i>	\$392,644
<u>Bristol Myers-Squibb</u>	2007	
Support of Local Events and Programs		\$24,290
Advertising in ADA Publications		\$120,994
Exhibiting (Scientific Sessions)		\$20,000
Scientific Sessions (Corporate Sponsored Symposia)		\$25,000
	<i>Sub-Total</i>	\$190,284
<u>Bristol Myers-Squibb</u>	2008	
Support of Local Events and Programs		\$45,198
Advertising in ADA Publications		\$114,450

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
Scientific Sessions (Corporate Symposia & Advance Program)		\$95,000
	<i>Sub-Total</i>	\$254,648
Bristol Myers-Squibb	2009	
Support of Local Events and Programs		\$23,522
Advertising in ADA Publications		\$113,030
Scientific Sessions (Corporate Symposia & Advance Program)		\$95,000
EXPO		\$1,000
	<i>Sub-Total</i>	\$232,551
Daiichi-Sankyo Pharmaceuticals	2009	
Support of Local Events and Programs		\$10,400
Advertising in ADA Publications		\$77,801
Scientific Sessions (2 Rotating Ads)		\$30,000
Scientific Sessions Exhibit		\$37,200
	<i>Sub-Total</i>	\$155,401
Eli Lilly & Company	2006	
Support of Gestational Diabetes Conference		\$15,000
Advanced Glycation End Products Research Conference		\$15,000
Make The Link! Diabetes/Cardiovascular Initiative		\$75,000
Cardiometabolic Risk Initiative		\$250,000
Beta Cell Research Conference		\$93,187
Support of Local Events and Programs		\$145,173
Advertising in ADA Publications		\$427,682
Expo		\$139,900
Exhibiting (Scientific Sessions)		\$138,000
Scientific Sessions (Corporate Sponsored Symposia)		\$75,000
Scientific Sessions Awards		\$20,000
Scientific Sessions (Bus Route Sponsorship)		\$50,000
PostGraduate Course Notepads		\$15,000
PostGraduate Course Showcase		\$2,000
	<i>Sub-Total</i>	\$1,460,942
Eli Lilly & Company	2007	
Cardiometabolic Risk Initiative		\$250,000
Make The Link		\$50,000
Inspired By Diabetes (Camp Scholarships)		\$50,000
ADA Youth Initiative		\$351,400
Foundation Donation		\$27,400
Support of Local Events and Programs		\$115,563
Advertising in ADA Publications		\$509,976
Expo		\$211,300

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
Membership		\$36,270
Scientific Sessions (Awards)		\$20,000
Scientific Sessions (Bus Route sponsorships)		\$100,000
Scientific Sessions (Corporate Sponsored Symposia)		\$25,000
Exhibiting (Scientific Sessions)		\$185,600
Scientific Sessions Awards (2008)		\$20,000
PostGraduate Course Notepads		\$15,000
PostGraduate Course Product Shwocase		\$5,000
PostGraduate Course Notepads		<u>\$15,000</u>
	<i>Sub-Total</i>	\$1,987,109
<u>Eli Lilly & Company</u>	2008	
Cardiometabolic Risk Initiative		\$250,000
Support of Local Events and Programs		\$211,050
Advertising in ADA Publications		\$526,089
Expo		\$202,250
Exhibiting (Scientific Sessions)		\$139,200
Scientific Sessions Awards		\$20,000
Scientific Sessions (Bus Route Sponsorship)		\$75,000
PostGraduate Course Notepads		\$15,000
PostGraduate Course Showcase		\$5,000
	<i>Sub-Total</i>	\$1,443,589
<u>Eli Lilly & Company</u>	2009	
ADA Camperships		\$50,000
Support of Local Events and Programs		\$137,148
Advertising in ADA Publications		\$540,253
Expo		\$142,600
Exhibiting (Scientific Sessions)		\$130,200
Scientific Sessions Awards		\$20,000
ADA Research Foundation		\$3,198
Health Disparities Forum		\$34,000
Diabetes & Cancer Conference		\$50,000
	<i>Sub-Total</i>	\$1,107,399
<u>GlaxoSmithKline</u>	2006	
A1C Research Study		\$300,000
Shaping America's Health		\$150,000
Cardiometabolic Risk Initiative		\$250,000
Make The Link! Diabetes/Cardiovascular Initiative		\$75,000
Support of Local Events and Programs		\$44,250
Advertising in ADA Publications		\$243,866
Expo		\$40,800
Scientific Sessions (Exhibiting)		\$154,000
Scientific Sessions (Patron Sponsorship)		\$60,000
Scientific Sessions (Registration Briefcase)		\$100,000
Scientific Sessions (Abstracts Online)		\$30,000

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
Scientific Sessions (Council Meeting)		\$10,000
Scientific Sessions (Corporate Sponsored Symposia)		\$25,000
Scientific Sessions (Bus Route Sponsorship)		\$35,000
	<i>Sub-Total</i>	\$1,532,916
GlaxoSmithKline	2007	
Support of Local Events and Programs		\$72,750
Advertising in ADA Publications		\$58,398
Expo		\$35,050
Scientific Sessions (Corporate Sponsored Symposia)		\$25,000
Exhibiting (Scientific Sessions)		\$10,500
	<i>Sub-Total</i>	\$296,698
GlaxoSmithKline	2008	
Support of Local Events and Programs		\$113,100
Advertising in ADA Publications		\$45,720
Expo		\$6,800
Scientific Sessions (Patron)		\$60,000
Scientific Sessions (Best of Sessions)		\$179,461
Scientific Sessions DVDs		\$73,039
Exhibiting (Scientific Sessions)		\$46,400
	<i>Sub-Total</i>	\$524,520
GlaxoSmithKline	2009	
Support of Local Events and Programs		\$14,793
Advertising in ADA Publications		\$32,480
Expo		\$3,200
	<i>Sub-Total</i>	\$50,473
Humana	2006	
Support of Local Events, Expo and Programs		\$56,288
	<i>Sub-Total</i>	\$56,288
Humana	2007	
Support of Local Events, Expo and Programs		\$58,800
	<i>Sub-Total</i>	\$58,800
Humana	2008	
Support of Local Events, Expo and Programs		\$64,025
	<i>Sub-Total</i>	\$64,025
Humana	2009	
Support of Local Events, Expo and Programs		\$92,375
	<i>Sub-Total</i>	\$92,375
Johnson & Johnson	2006	

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
Support of Local Events, Expo and Programs		<u>\$16,268</u>
<i>Sub-Total</i>		\$16,268
Johnson & Johnson	2007	
Support of Local Events, Expo and Programs		<u>\$17,287</u>
<i>Sub-Total</i>		\$17,287
Johnson & Johnson	2008	
Support of Local Events, Expo and Programs		<u>\$22,919</u>
<i>Sub-Total</i>		\$22,919
Johnson & Johnson	2009	
Support of Local Events, Expo and Programs		<u>\$145,901</u>
<i>Sub-Total</i>		\$145,901
LifeScan, a Johnson & Johnson Company	2006	
Diabetes Care Supplement		\$158,644
Consumer Survey		\$2,800
Support of Local Events and Programs		\$125,225
Advertising in ADA Publications		\$385,000
Expo		\$11,900
Exhibiting (Scientific Sessions)		\$127,400
Diabetes Care Coalition		<u>\$400,000</u>
<i>Sub-Total</i>		\$1,211,769
LifeScan, a Johnson & Johnson Company	2007	
Support of Local Events and Programs		\$105,385
Advertising in ADA Publications		\$189,501
Expo		\$33,420
Diabetes Care (CD of Clinical Practice Recommendations)		\$247,060
Exhibiting (Scientific Sessions)		\$130,500
Diabetes Care Coalition		<u>\$400,000</u>
<i>Sub-Total</i>		\$1,105,866
LifeScan, a Johnson & Johnson Company	2008	
Support of Local Events and Programs		\$125,449
Advertising in ADA Publications		\$70,648
Expo		\$19,255
Exhibiting (Scientific Sessions)		<u>\$104,400</u>
<i>Sub-Total</i>		\$319,752
LifeScan, a Johnson & Johnson Company	2009	
Support of Local Events and Programs		\$24,150
Expo		\$18,300
Asian American Program		\$35,000
Exhibiting (Scientific Sessions)		<u>\$93,000</u>
<i>Sub-Total</i>		\$170,450
Medtronic Diabetes	2006	

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
National Support		\$30,000
Advertising in ADA Publications		\$104,864
EXPO		\$31,500
Support of Local Events and Programs		\$29,215
	<i>Sub-Total</i>	\$195,579
Medtronic Diabetes	2007	
Support of Local Events and Programs		\$57,550
Advertising in ADA Publications		\$59,400
Expo		\$38,315
Exhibiting (Scientific Sessions)		\$101,500
Scientific Sessions (Corporate Sponsored Symposia)		\$25,000
Medtronic Foundation Grant		\$53,800
	<i>Sub-Total</i>	\$335,565
Medtronic Diabetes	2008	
Support of Local Events and Programs		\$173,320
Advertising in ADA Publications		\$41,580
Expo		\$37,168
Exhibiting (Scientific Sessions)		\$101,500
Scientific Sessions (Corporate Symposia)		\$25,000
Product Education Showcase at Postgraduate Course		\$5,000
Medtronic Foundation Grant		\$3,500
	<i>Sub-Total</i>	\$387,068
Medtronic Diabetes	2009	
Support of Local Events and Programs		\$113,724
Expo		\$39,832
Exhibiting (Scientific Sessions)		\$77,500
Scientific Sessions (Corporate Symposia)		\$50,000
Product Education Showcase at Postgraduate Course		\$5,000
	<i>Sub-Total</i>	\$286,056
Merck & Company	2006	
A1C Research Study		\$300,000
Research Conference on Advanced Glycation Products		\$5,000
Support of Local Events and Programs		\$18,110
Advertising in ADA Publications		\$122,000
Exhibiting (Scientific Sessions)		\$170,400
Scientific Sessions (Corporate Sponsored Symposia)		\$50,000

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
Scientific Sessions (Bottled Water)		\$15,000
Scientific Sessions (Sponsorship of Symposia)		\$10,000
Scientific Sessions (Meeting Notebooks)		\$110,000
	<i>Sub-Total</i>	\$860,500
Merck & Company	2007	
Self-Assessment Course On Diabetes		\$425,000
Cardiometabolic Risk Initiative		\$260,000
Support of Local Events and Programs		\$40,950
Advertising in ADA Publications		\$173,436
Book Purchase		\$1,509,309
Exhibiting (Scientific Sessions)		\$159,500
Scientific Sessions (Corporate Sponsored Symposia)		\$25,000
Scientific Sessions (Support of Educational Session)		\$10,000
Scientific Sessions (Council Meeting)		\$10,000
Scientific Sessions (Patron Sponsor)		\$60,000
Scientific Sessions (Meeting Notebooks)		\$110,000
Scientific Sessions (Meeting Notebooks)		\$120,000
Scientific Sessions (Patron Sponsor)		\$60,000
PostGraduate Course (Meeting Guide)		\$35,000
PostGraduate Course (Patron Sponsor)		<u>\$20,000</u>
	<i>Sub-Total</i>	\$3,100,195
Merck & Company	2008	
Patient Management Problem Project		\$220,000
Cardiometabolic Risk Initiative		\$188,000
Support of Local Events and Programs		\$140,750
Advertising in ADA Publications		\$180,840
EXPO		\$1,000
Exhibiting (Scientific Sessions)		\$171,100
Scientific Sessions (Patron Sponsor)		\$60,000
Scientific Sessions (Meeting Notebooks)		\$120,000
PostGraduate Course (Meeting Guide)		\$35,000
PostGraduate Course (Patron Sponsor)		\$20,000
ADA Clinical/Translational Research Grant		<u>\$300,000</u>
	<i>Sub-Total</i>	\$1,436,690
Merck & Company	2009	
Cardiometabolic Risk Initiative		\$200,000
Support of Local Events and Programs		\$58,100
Advertising in ADA Publications		\$404,418
Exhibiting (Scientific Sessions)		\$108,500
Scientific Sessions (Corporate Symposia)		\$50,000
Scientific Sessions (Patron & Benefactor Sponsor)		\$95,000
ADA Research Fellowship Award Program		\$150,000
Diabetes & Cancer Consensus Development Conference		\$10,000

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
Health Disparities Forum		\$35,000
Postgraduate Course (Meeting Guide)		\$35,000
Postgraduate Course (Patron)		\$20,000
<i>Sub-Total</i>		\$1,166,018
Merck/Schering-Plough Pharmaceuticals	2006	
Advertising in ADA Publications		\$21,194
Exhibiting (Scientific Sessions)		\$112,000
Scientific Sessions (Corporate Symposia Fee)		\$25,000
<i>Sub-Total</i>		\$158,194
Merck/Schering-Plough Pharmaceuticals	2007	
Cardiometabolic Risk Initiative		\$65,000
Exhibiting (Scientific Sessions)		\$116,000
Scientific Sessions (Corporate Symposia Fee)		\$25,000
<i>Sub-Total</i>		\$206,000
Merck/Schering-Plough Pharmaceuticals	2008	
Cardiometabolic Risk Initiative		\$62,000
Exhibiting (Scientific Sessions)		\$11,600
Scientific Sessions (Educational Support)		\$10,000
Scientific Sessions (Corporate Symposia Fee)		\$25,000
<i>Sub-Total</i>		\$108,600
Merck/Schering-Plough Pharmaceuticals	2009	
Cardiometabolic Risk Initiative		\$60,000
Exhibiting (Scientific Sessions)		\$27,900
Scientific Sessions (Benefactor)		\$35,000
<i>Sub-Total</i>		\$122,900
Novartis Pharmaceuticals	2006	
Make The Link! Diabetes/Cardiovascular Initiative		\$75,000
Support of Local Events and Programs		\$24,750
EXPO		\$28,000
Exhibiting (Scientific Sessions)		\$58,200
Scientific Sessions (Corporate Symposia Fees)		\$25,000
PostGraduate Course (Corporate Symposia Fees)		\$15,000
I Decide To Fight Diabetes Campaign		\$350,000
African American Program		\$575,000
Cardiometabolic Risk Initiative		\$250,000
Latino Education Initiative (1st Payment of Grant)		\$692,500
Diabetes Care Coalition		\$400,000
<i>Sub-Total</i>		\$2,493,450
Novartis Pharmaceuticals	2007	
Latino Initiative (2nd Payment of Grant)		\$757,500
Support of Local Events and Programs		\$152,350
Advertising in ADA Publications		\$110,730
EXPO		\$18,100

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
Exhibiting (Scientific Sessions)		\$2,600
Scientific Sessions (Corporate Symposia Fees)		\$50,000
Diabetes Care Coalition		\$400,000
<i>Sub-Total</i>		\$1,491,280
Novartis Pharmaceuticals	2008	
Cardiometabolic Risk Initiative		\$250,000
Support of Local Events and Programs		\$1,500
Advertising in ADA Publications		\$20,080
EXPO		\$8,000
Exhibiting (Scientific Sessions)		\$8,400
<i>Sub-Total</i>		\$287,980
Novartis Pharmaceuticals	2009	
Support of Local Events and Programs		\$17,295
EXPO		\$6,200
<i>Sub-Total</i>		\$23,495
Novo Nordisk Inc.	2006	
Ecnomic Cost of Diabetes Study		\$150,000
Psychology Meeting		\$15,000
Research Studies		\$120,000
Support of Local Events and Programs		\$181,450
Advertising in ADA Publications		\$400,611
EXPO		\$101,750
Diabetes Care Coalition		\$400,000
Scientific Sessions Sponsorships	<i>Sub-Total</i>	\$1,878,611
Novo Nordisk	2007	
Safe at School Trainings		\$100,000
Diabetes Screening Project		\$175,000
Support of Local Events and Programs		\$340,185
Advertising in ADA Publications		\$375,320
Expo		\$9,780
Scientific Sessions Sponsorships		\$150,000
Exhibiting (Scientific Sessions)		\$287,100
PostGraduate Course (Corporate Symposia)		\$15,000
Diabetes Care Coalition		\$400,000
<i>Sub-Total</i>		\$2,122,385
Novo Nordisk	2008	
Safe at School Trainings		\$200,000
Incretin Webcast		\$159,995
Support of Local Events and Programs		\$498,440
Advertising in ADA Publications		\$622,795
Expo		\$122,880
Scientific Sessions Sponsorships		\$122,000

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
Exhibiting (Scientific Sessions)		\$287,100
PostGraduate Course (Corporate Symposia)		\$15,000
	<i>Sub-Total</i>	\$2,028,210
Novo Nordisk	2009	
Support of Local Events and Programs		\$431,283
Advertising in ADA Publications		\$329,233
Expo		\$94,375
Scientific Sessions (3 corporate symposia & Hotel Key Cards)		\$210,000
Exhibiting (Scientific Sessions)		\$306,900
Postgraduate Course (Key Cards & Corporate Symposia)		\$25,000
Research Foundation		\$400,000
Legal Advocacy		\$250,000
Diabetes & Cancer Conference		\$50,000
Diabetes Management Initiative		\$112,500
	<i>Sub-Total</i>	\$2,209,292
Pfizer Inc.	2006	
Project Power		\$200,000
Support of Local Events and Programs		\$137,625
Advertising in ADA Publications		\$500,000
Expo		\$115,400
Scientific Sessions Exhibiting		\$196,000
Scientific Sessions Sponsorships		\$160,000
Scientific Sessions (Corporate Sponsored Symposia fees)		\$100,000
PostGraduate Course (Corporate Sponsored Symposia Fee)		\$15,000
	<i>Sub-Total</i>	\$1,424,025
Pfizer Inc.	2007	
Cardiometabolic Risk Initiative		\$750,000
Diabetes Community Screenings		\$250,000
Diabetes Screening Research study		\$167,900
Support of Local Events and Programs		\$127,650
EXPO		\$135,550
Scientific Sessions Sponsorships		\$294,000
Scientific Sessions (Corporate Symposia fees)		\$75,000
	<i>Sub-Total</i>	\$2,245,882
Pfizer Inc.	2008	
Primary Care Needs Assessment		\$250,000
Support of Local Events and Programs		\$16,000
EXPO		\$16,500
Scientific Sessions Sponsorships		\$85,000
Postgraduate Course Patron Supporter		\$10,000

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
Advertising in ADA Publications		\$251,591
Exhibiting (Scientific Sessions)		<u>\$75,400</u>
<i>Sub-Total</i>		\$704,491
Pfizer Inc.	2009	
Support of Local Events and Programs		\$72,281
EXPO		\$4,200
Cardiometabolic Risk Initiative		\$250,000
Stop Diabetes		\$50,000
Exhibiting (Scientific Sessions)		\$62,000
Advertising in ADA Publications		<u>\$139,540</u>
<i>Sub-Total</i>		\$578,021
Roche Pharmaceuticals Corporation	2009	
ADA's Master's Course		<u>\$500,000</u>
		\$500,000
Roche Diagnostics Corporation	2006	
Support of Local Events and Programs		\$124,925
Advertising in ADA Publications		\$249,564
EXPO		\$27,400
Scientific Sessions Exhibiting		\$57,500
In-Kind Contributions For Diabetes Camps		<u>\$60,781</u>
<i>Sub-Total</i>		\$520,170
Roche Diagnostics Corporation	2007	
Support of Local Events and Programs		\$151,420
Advertising in ADA Publications		\$249,599
Indianapolis Kiss-a-Pig Event		\$15,691
EXPO		\$55,650
Scientific Sessions Exhibiting		\$58,000
Scientific Sessions (Corporate Sponsored Symposia Fee)		<u>\$25,000</u>
<i>Sub-Total</i>		\$555,360
Roche Diagnostics Corporation	2008	
Support of Local Events and Programs		\$210,848
Advertising in ADA Publications		\$232,488
EXPO		\$65,800
Scientific Sessions Exhibiting		<u>\$72,500</u>
<i>Sub-Total</i>		\$581,636
Roche Diagnostics Corporation	2009	
Support of Local Events and Programs		\$122,741
Advertising in ADA Publications		\$146,200
EXPO		\$25,100
Scientific Sessions Exhibiting		<u>\$77,500</u>
<i>Sub-Total</i>		\$371,541

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
sanofi-aventis	2006	
Cardiometabolic Risk Initiative		\$600,000
Insulin Grand Rounds Program		\$150,000
Doing Better: Tools for Diabetes Care		\$125,000
Support of Local Events and Programs		\$84,525
Advertising in ADA Publications		\$327,391
EXPO		\$76,850
Scientific Sessions (Exhibiting)		\$215,600
Scientific Sessions (Sponsorships)		\$160,000
Scientific Sessions (Corporate Sponsored Symposia)		\$75,000
Diabetes Care Coalition		\$400,000
PostGraduate Course (Lanyards Sponsorships)		\$10,000
	<i>Sub-Total</i>	\$2,224,366
sanofi-aventis	2007	
Cardiometabolic Risk Initiative (Year Two of Three)		\$600,000
Feria Outdoor Festival Program		\$65,000
Support of Local Events and Programs		\$78,320
Advertising in ADA Publications		\$466,461
EXPO		\$244,950
Scientific Sessions (Corporate Symposia fees)		\$50,000
Scientific Sessions (Sponsorships)		\$140,000
2008 Scientific Sessions (Sponsorships)		\$70,000
Diabetes Care Coalition		\$400,000
	<i>Sub-Total</i>	\$2,114,731
sanofi-aventis	2008	
Cardiometabolic Risk Initiative (Year 3 of 3)		\$600,000
Postgraduate Course (Lanyards)		\$10,000
Support of Local Events and Programs		\$161,709
Advertising in ADA Publications		\$796,389
EXPO		\$180,250
Scientific Sessions (Corporate Symposia, Attendee Badges, Lanyards and Posters2View)		\$225,000
Scientific Sessions (Exhibit)		\$287,100
	<i>Sub-Total</i>	\$2,260,448
sanofi-aventis	2009	
Support of Local Events and Programs		\$128,355
Advertising in ADA Publications		\$487,961
EXPO		\$153,000
Scientific Sessions (Corporate Symposia & Posters2View)		\$135,000
Scientific Sessions (Exhibiting)		\$77,500
Diabetes & Cancer Conference		\$50,000

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
Advocacy		\$44,087
	<i>Sub-Total</i>	\$1,075,903
SOILL	2006	
ADA Research Foundation		\$100,000
	<i>Sub-Total</i>	\$100,000
Solvay Pharmaceuticals	2008	
Men's Health Campaign		\$2,400,000
	<i>Sub-Total</i>	\$2,400,000
Solvay Pharmaceuticals	2009	
Men's Health Campaign		\$690,000
	<i>Sub-Total</i>	\$690,000
Takeda Pharmaceuticals North America	2006	
Advanced Glycation Research Conference		\$15,000
Cardiovascular Research Grant		\$700,000
Cardiometabolic Risk Initiative		\$250,000
Support of Local Events and Programs		\$67,250
Advertising in ADA Publications		\$172,903
EXPO		\$63,000
Scientific Sessions Sponsorships		\$171,000
Scientific Sessions Corporate Sponsored Symposia		\$50,000
	<i>Sub-Total</i>	\$1,489,153
Takeda Pharmaceuticals North America	2007	
Cardiovascular Research Grant		\$288,000
Cardiometabolic Risk Initiative		\$250,000
Support of Local Events and Programs		\$232,090
Advertising in ADA Publications		\$243,603
EXPO		\$225,900
Scientific Sessions Sponsorships		\$160,000
Scientific Sessions Corporate Sponsored Symposia		\$50,000
Scientific Sessions Exhibiting		\$116,000
PostGraduate Course corporate Sponsored Symposia		\$15,000
	<i>Sub-Total</i>	\$1,993,593
Takeda Pharmaceuticals North America	2008	
ADA Research Grant		\$1,056,500
Physician Self-Assessment Program		\$397,250
Patient Management Problem Project		\$163,550
Advertising in ADA Publications		\$330,739
EXPO		\$141,200
Scientific Sessions Sponsorships		\$405,000
Best of Sessions Webcast		\$178,661
Scientific Sessions Exhibiting		\$116,000
PostGraduate Course Sponsorships		\$45,000

American Diabetes Association
Pharmaceutical Industry Revenues
2006-2009

Company/Source	Year	Revenue
	<i>Sub-Total</i>	\$2,833,900
Takeda Pharmaceuticals North America	2009	
Support of Local Events and Programs		\$141,603
Cardiometabolic Risk Initiative		\$250,000
ADA Research Foundation		\$464,000
Advertising in ADA Publications		\$21,004
EXPO		\$162,850
Scientific Sessions Abstracts2View		\$70,000
Scientific Sessions Corporate Symposia		\$50,000
Scientific Sessions E-mail Stations		\$115,000
Scientific Sessions 2 Rotating Ads		\$30,000
Scientific Sessions Exhibitng		\$124,000
e (Corporate Symposia, Product Education Showcase)		<u>\$20,000</u>
	<i>Sub-Total</i>	\$1,448,457